Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab-Reference-Cited by-同舟云学术

Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab

Published:2018-01 Issue: Volume:115 Page:71-74
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Sato Koichi,Akamatsu Hiroaki,Murakami Eriko,Sasaki Seigo,Kanai Kuninobu,Hayata Atsushi,Tokudome Nahomi,Akamatsu Keiichiro,Koh Yasuhiro,Ueda Hiroki,Nakanishi Masanori,Yamamoto Nobuyuki

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference8 articles.

1. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

2. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N. Engl. J. Med.,2015

3. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N. Engl. J. Med.,2016

4. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma;Weber;J. Clin. Oncol.,2017

5. Pembrolizumab cutaneous adverse events and their association with disease progression;Sanlorenzo;JAMA Dermatol.,2015

Cited by 330 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of Immune-Related Adverse Events and the Efficacy of Anti–PD-(L)1 Monotherapy in Non–Small Cell Lung Cancer: Adjusting for Immortal-Time Bias;Cancer Research and Treatment;2024-07-15

3. Early discontinuation of immune checkpoint inhibitor therapy prior to disease progression in patients with metastatic non-small cell lung cancer: a survival analysis;Frontiers in Oncology;2024-06-21

5. Predictive capacity of immune‐related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma;Cancer Medicine;2024-06